Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet Oncology

Volumn 18, Issue 3, 2017, Pages 297-311

  Zelenetz, Andrew D ^a   Barrientos, Jacqueline C ^b   Brown, Jennifer R ^c   Coiffier, Bertrand ^d   Delgado, Julio ^e   Egyed, Miklós ^f   Ghia, Paolo ^g   Illés, Árpád ^h   Jurczak, Wojciech ⁱ   Marlton, Paula ^j   Montillo, Marco ^k   Morschhauser, Franck ^l   Pristupa, Alexander S ^m   Robak, Tadeusz ⁿ   Sharman, Jeff P ^o   Simpson, David ^p   Smolej, Lukáš ^q   Tausch, Eugen ^r   Adewoye, Adeboye H ^s   Dreiling, Lyndah K ^s   Kim, Yeonhee ^s   Stilgenbauer, Stephan ^r   Hillmen, Peter ^t   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e HOSPITAL CLÍNIC   (Spain)

^f Kaposi Mor Teaching Hospital   (Hungary)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h UNIVERSITY OF DEBRECEN   (Hungary)

ⁱ JAGIELLONIAN UNIVERSITY   (Poland)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k OSPEDALE NIGUARDA CA GRANDA   (Italy)

^l Univ Lille   (France)

^m Ryazan Regional Clinical Hospital   (Russian Federation)

ⁿ MEDICAL UNIVERSITY OF LODZ   (Poland)

^o Willamette Valley Cancer Center   (United States)

^p NORTH SHORE HOSPITAL   (New Zealand)

^q UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^r UNIVERSITY OF ULM   (Germany)

^s GILEAD SCIENCES   (United States)

^t ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BENDAMUSTINE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; IDELALISIB; PLACEBO; PROTEIN P53; RITUXIMAB; ANTINEOPLASTIC AGENT; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIAL PNEUMONIA; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELLULITIS; CHILL; CHROMOSOME DELETION; CHROMOSOME DELETION 17P; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GENE MUTATION; HEADACHE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMMUNOGLOBULIN HEAVY CHAIN GENE; INFECTION; INFUSION RELATED REACTION; LEUKEMIA RELAPSE; LIVER DISEASE; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; LUNG MYCOSIS; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; RESPIRATORY TRACT INFECTION; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROSEPSIS; VIRUS PNEUMONIA; VOMITING; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PURINES; QUINAZOLINONES; RITUXIMAB; SALVAGE THERAPY; SURVIVAL RATE;

EID: 85010951468     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30671-4     Document Type: Article

References (22)

1. 1 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. Version 1. http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf, 2016 (accessed Jan 20, 2016).
2. 2 Grever, MR, Lucas, DM, Dewald, GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25 (2007), 799–804.
3. 3 Zenz, T, Eichhorst, B, Busch, R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28 (2010), 4473–4479.
4. 4 Dohner, H, Stilgenbauer, S, Benner, A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000), 1910–1916.
5. 5 Hallek, M, Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol 90 (2015), 446–460.
6. 6 Blunt, MD, Steele, AJ, Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia. Leuk Res Rep 4 (2015), 60–63.
7. 7 Zydelig (idelalisib) tablets for oral use. Full prescribing information, 2014, Gilead Sciences, Foster City, CA http://www.zydelig.com/include/media/pdf/full-prescribing-information.pdf (accessed Feb 2, 2016).
8. 8 European Medicines Agency. Zydelig. Summary of product characterisations. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003843/WC500175377.pdf, 2015 (accessed Feb 2, 2016).
9. 9 Hallek, M, Cheson, BD, Catovsky, D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (2008), 5446–5456.
10. 10 Stilgenbauer, S, Schnaiter, A, Paschka, P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123 (2014), 3247–3254.
11. 11 Cheson, BD, Byrd, JC, Rai, KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30 (2012), 2820–2822.
12. 12 Li X, Wulfsohn M, Koch G. Statistical considerations on secondary endpoints after trial is stopped at an interim analysis. FDA/Industry Statistics Workshop; Washington, DC; Sept 22–24, 2014.
13. 13 Furman, RR, Sharman, JP, Coutre, SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370 (2014), 997–1007.
14. 14 Brown, JR, Byrd, JC, Coutre, SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 123 (2014), 3390–3397.
15. 15 Zelenetz, AD, Lamanna, N, Kipps, TJ, et al. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood, 124, 2014, 1986 (abstract).
16. 16 Chanan-Khan, A, Cramer, P, Demirkan, F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17 (2016), 200–211.
17. 17 Stilgenbauer, S, Eichhorst, BF, Schetelig, J, et al. Venetoclax (ABT-199/GDC-0199) monotherapy induces deep remissions, including complete remission and undetectable MRD, in ultra-high risk relapsed/refractory chronic lymphocytic leukemia with 17p deletion: results of the pivotal international phase 2 study. Blood 126 (2015), LBA–LB6 (abstract).
18. 18 Coutre, SE, Barrientos, JC, Brown, JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 56 (2015), 2779–2786.
19. 19 Balfour, JA, Goa, KL, Bendamustine. Drugs 61 (2001), 631–638 discussion 9–40.
20. 20 Sharman, JP, Coutre, SE, Furman, RR, et al. Second interim analysis of a phase 3 study of idelalisib (Zydelig) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Blood, 124, 2014, 330 (abstract).
21. 21 Burger, JA, Tedeschi, A, Barr, PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373 (2015), 2425–2437.
22. 22 Byrd, JC, Brown, JR, O'Brien, S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371 (2014), 213–223.